Patients that are having Covid-19 Disease After the First Dose of Covid-Vaccine
DOI:
https://doi.org/10.31964/mltj.v7i2.390Keywords:
Covid-19 disease, Covid-19 vaccine, Reverse Transcription-Polymerase Chain Reaction (RT-PCR)Abstract
There is no effective treatment for the Covid-19 disease that is still impacting the whole world. It considered that vaccines, one of the effective means to prevent infectious diseases, will play a significant role in protecting from the Covid-19 Disease. Vaccinations generals performed before exposure. We aimed to follow the clinical and laboratory progress of patients who got Covid-19 after the first dose of the Covid-19 vaccine and to evaluate the changes that may occur in antibody formation. 13 patients, who received the first dose of COVID 19 vaccine Coronovac as of 14.01.2021 when vaccination started in Adıyaman University Training and Research Hospital/Turkey, who had symptoms after the vaccine and whose real-time PCR found to be positive, were included in the study. After the first dose of the Covid-19 vaccine, 13 patients exam. Three of our patients were female, and 10 of them were male. The average age was 38.8. British variant detected in 4 of our patients; 1 of them was female. Contact times differed between 3 and 5 days. The most common symptoms were muscle-joint pain (53.8), weakness-fatigue (46.2), fever (38.5), and headache (30.8). Three of our patients, being one female, received inpatient treatment. Furthermore, our five patients who checked regarding Sars cov-2 IgG became positive in the first month. No adverse changes in the course of the illness observed in the patients were RT-PCR positive after the first dose of the Covid-19 vaccine. Antibody response detected at the end of the first month. Vaccination is an effective method for taking infectious diseases under control but adhering to personal protective measures still maintains their importance.References
Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, Edwards KM, Gandhi R, Muller WJ, O'Horo JC, Shoham S, Murad MH, Mustafa RA, Sultan S, Falck-Ytter Y. (2020). Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis. 2020 Apr 27, ciaa478. doi: 10.1093/cid/ciaa478.
Dong, L., Hu, S., & Gao, J. (2020). Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug discoveries & therapeutics, 14(1), 58-60.
Gallagher, T., & Lipsitch, M. (2019). Postexposure effects of vaccines on infectious diseases. Epidemiologic reviews, 41(1), 13-27.
Guan, W. J., Ni, Z. Y., Hu, Y., Liang, W. H., Ou, C. Q., He, J. X., ... & Zhong, N. S. (2020). Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine, 382(18), 1708-1720.
Henderson, D. A., Inglesby Jr, T. V., O'Toole, T., & Mortimer, P. P. (2003). Can postexposure vaccination against smallpox succeed?. Clinical Infectious Diseases, 36(5), 622-629.
Jin, Z., Du, X., Xu, Y. et al. (2020). Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature, 582, 289–293. https://doi.org/10.1038/s41586-020-2223-y
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., & Lessler, J. (2020). The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of internal medicine, 172(9), 577-582.
Lee, Y. H., Hong, C. M., Kim, D. H., Lee, T. H., & Lee, J. (2020). Clinical course of asymptomatic and mildly symptomatic patients with coronavirus disease admitted to community treatment centers, South Korea. Emerging infectious diseases, 26(10), 2346.
Lim, H. X., Lim, J., Jazayeri, S. D., Poppema, S., & Poh, C. L. (2020). Development of multi-epitope peptide-based vaccines against SARS-CoV-2. Biomedical Journal.
Massoudi, M. S., Barker, L., & Schwartz, B. (2003). Effectiveness of postexposure vaccination for the prevention of smallpox: results of a delphi analysis. The Journal of infectious diseases, 188(7), 973-976.
Onsun N, Kaya G, Işık BG, Güneş B. (2021). A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report. Health Promot Perspect; 11(2),261-262. doi:10.34172/hpp.2021.32
Rawat, K., Kumari, P., & Saha, L. (2020). COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. European journal of pharmacology, 173751.
Sheppeard, V., Forssman, B., Ferson, M. J., Moreira, C., Campbell-Lloyd, S., Dwyer, D. E., & McAnulty, J. M. (2009). The effectiveness of prophylaxis for measles contacts in NSW. New South Wales public health bulletin, 20(6), 81-85.
Soiza, R. L., Scicluna, C., & Thomson, E. C. (2021). Efficacy and safety of COVID-19 vaccines in older people. Age and Ageing, 50(2), 279-283.
Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. (2021). Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. The Lancet, 398(10296), 213–22. Available from: http://www.thelancet.com/article/S014067362101429X/fulltext
Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., & Riley, S. (2019). S.[van Elsland], E. Volz, H. Wang, Y. Wang, X. Xi, CA Donnelly, AC Ghani, NM Ferguson, Estimates of the severity of coronavirus disease, 30243-7.
Xu, X. W., Wu, X. X., Jiang, X. G., Xu, K. J., Ying, L. J., Ma, C. L., & Li, L. J. (2020). Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. bmj, 368.
Dong, L., Hu, S., & Gao, J. (2020). Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug discoveries & therapeutics, 14(1), 58-60.
Gallagher, T., & Lipsitch, M. (2019). Postexposure effects of vaccines on infectious diseases. Epidemiologic reviews, 41(1), 13-27.
Guan, W. J., Ni, Z. Y., Hu, Y., Liang, W. H., Ou, C. Q., He, J. X., ... & Zhong, N. S. (2020). Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine, 382(18), 1708-1720.
Henderson, D. A., Inglesby Jr, T. V., O'Toole, T., & Mortimer, P. P. (2003). Can postexposure vaccination against smallpox succeed?. Clinical Infectious Diseases, 36(5), 622-629.
Jin, Z., Du, X., Xu, Y. et al. (2020). Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature, 582, 289–293. https://doi.org/10.1038/s41586-020-2223-y
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., & Lessler, J. (2020). The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of internal medicine, 172(9), 577-582.
Lee, Y. H., Hong, C. M., Kim, D. H., Lee, T. H., & Lee, J. (2020). Clinical course of asymptomatic and mildly symptomatic patients with coronavirus disease admitted to community treatment centers, South Korea. Emerging infectious diseases, 26(10), 2346.
Lim, H. X., Lim, J., Jazayeri, S. D., Poppema, S., & Poh, C. L. (2020). Development of multi-epitope peptide-based vaccines against SARS-CoV-2. Biomedical Journal.
Massoudi, M. S., Barker, L., & Schwartz, B. (2003). Effectiveness of postexposure vaccination for the prevention of smallpox: results of a delphi analysis. The Journal of infectious diseases, 188(7), 973-976.
Onsun N, Kaya G, Işık BG, Güneş B. (2021). A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report. Health Promot Perspect; 11(2),261-262. doi:10.34172/hpp.2021.32
Rawat, K., Kumari, P., & Saha, L. (2020). COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. European journal of pharmacology, 173751.
Sheppeard, V., Forssman, B., Ferson, M. J., Moreira, C., Campbell-Lloyd, S., Dwyer, D. E., & McAnulty, J. M. (2009). The effectiveness of prophylaxis for measles contacts in NSW. New South Wales public health bulletin, 20(6), 81-85.
Soiza, R. L., Scicluna, C., & Thomson, E. C. (2021). Efficacy and safety of COVID-19 vaccines in older people. Age and Ageing, 50(2), 279-283.
Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. (2021). Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. The Lancet, 398(10296), 213–22. Available from: http://www.thelancet.com/article/S014067362101429X/fulltext
Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., & Riley, S. (2019). S.[van Elsland], E. Volz, H. Wang, Y. Wang, X. Xi, CA Donnelly, AC Ghani, NM Ferguson, Estimates of the severity of coronavirus disease, 30243-7.
Xu, X. W., Wu, X. X., Jiang, X. G., Xu, K. J., Ying, L. J., Ma, C. L., & Li, L. J. (2020). Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. bmj, 368.
Downloads
Published
2022-01-05
How to Cite
Sayiner, H. S., Vural, A., Doğan, F., Parlak, S., & Bakirhan, F. (2022). Patients that are having Covid-19 Disease After the First Dose of Covid-Vaccine. Medical Laboratory Technology Journal, 7(2), 194–200. https://doi.org/10.31964/mltj.v7i2.390
Issue
Section
Articles
License
Publishing your paper with Medical Laboratory Technology Journal (MLTJ) means that the author or authors retain the copyright in the paper. MLTJ granted an author(s) rights to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by MLTJ in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.
MLTJ journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially. MLTJ journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:
BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.SA: If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
